Scientist, Viral Gene Therapy

The mission of Ginkgo’s mammalian team is to engineer new and innovative tools for gene and cell therapy. We are looking for biologists who can expand our expertise, set priorities, propose and execute experiments, organize and present data. Creativity and practical “get it done” energy in a truly interdisciplinary environment are requirements. 

Responsibilities

• Significant experience with cell culture, in vitro modeling and analysis (e.g., qPCR, Luminex, flow cytometry)
• Experience with the molecular biology of gene expression (e.g., enhancers, promoters, inducible transcription/translation), including vector design and construction
• Experience with cell signaling, inflammation, or systems biology approaches a plus
• Knowledge of lentiviruses, AAV, and packaging systems preferred
• Experience with high throughput approaches and automation for pooled and arrayed screening preferred
• Flexibility to share occasional weekend cell culture duties for this role is preferred

Qualifications

• Ph.D. in molecular biology, cell therapy, genetics, or relevant field with 0-2 years hands on lab experience
• Fluency in mammalian cell culture and transfection/transduction techniques
• Experience with inducible/sensing systems preferred Ability to independently organize, communicate, and manage deliverables and timelines 
• Some experience translating data from in vitro experiments to in vivo study design is preferred
• Mentoring generously, learning gracefully, daring solutions, and comfort working at the edge of the knowledge frontier are requirements for this position

#LI-MB1

To learn more about Ginkgo, check out some recent press:

What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)

Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)

Ginkgo Bioworks Is Turning Human Cells into On-Demand Factories (WIRED)

Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (WSJ)

The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes)

The engineering of living organisms could soon start changing everything (The Economist)

Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg)

Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters)

Can This Company Convince You to Love GMOs? (The Atlantic)

This food tech startup just raised $90 million to make it easier to invent new plant-based meats (Fast Company) 

We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.  

We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology.

It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees and employment applicants.

Apply for this job